Work with a murine model demonstrated that injection of anti-CD26 monoclonal antibodies decreased the severity of GVHD by decreasing IL-26 production, while graft-versus-leukemia effect was still maintained, resulting in prolonged survival [13]. The gene discussed is DPP4; the disease is leukemia.